Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)

Current Pharmaceutical Design

Volumn 12, Issue 26, 2006, Pages 3347-3358

  de Weck, A L ^a   Gamboa, P M ^b   Esparza, R ^a   Sanz, M L ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL DE BASURTO   (Spain)

Author keywords

Aspirin; Basophils; Flowcytometry; Hypersensitivity; Leukotriene release; LTC4; NSAID

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; BETA LACTAM ANTIBIOTIC; COMPLEMENT COMPONENT C5A; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; DIPYRONE; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE; IBUPROFEN; IMMUNOGLOBULIN E; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE E4; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E2; ROFECOXIB; TACROLIMUS;

ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; ASTHMA; CHRONIC INFLAMMATION; CLINICAL FEATURE; CROSS REACTION; DIAGNOSTIC VALUE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FLOW CYTOMETRY; GENETIC POLYMORPHISM; HISTAMINE RELEASE; HUMAN; IMMUNOPATHOGENESIS; MAST CELL; NOSE POLYP; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROVOCATION TEST; RELIABILITY; RESPIRATORY TRACT ALLERGY; REVIEW; RHINOSINUSITIS; SENSITIVITY AND SPECIFICITY; SKIN ALLERGY; SKIN TEST; URTICARIA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DRUG HYPERSENSITIVITY; HUMANS;

EID: 33748546601     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778193971     Document Type: Review

References (180)

1. Widal MF, Abrani P, Lermoyez J. Anaphylaxie et idiosyncrasie. Presse Méd 1922; 30: 189-192 - Reprinted in Allergy Proc 1993; 14: 373-376.
2. Samter M, Beers RF. Concerning the nature of intolerance to aspirin J. Allergy 1967; 40: 281-293.
3. Szczeklik A, Stevenson D. Aspirin-induced asthma: Advances in pathogenesis, diagnosis and management. J Allergy Clin Immunol 2003; 111: 913-921.
4. Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhard J, Gladysz U, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003; 58: 1084-1066.
5. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and implications in clinical practice. BMJ 2004; 328(7437): 434.
6. Faich GA, Adverse drug reaction monitoring. N Engl J Med 1986; 314: 1589-1592.
7. Szczeklik, Stevenson DD. Aspirin-induced asthma: Advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104: 5-13.
8. Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004; 24: 491-505.
9. Bush RK, Asbury DW. Aspirin-sensitive asthma. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Blackwell Scientific, Oxford, 2nd ed., 2000; pp. 1315-1325.
10. Hamad AM, Sutcliffe AM, Knoy AJ. Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 2004; 64: 2417-2432.
11. Sainte-Laudy J. Nine cases of suspected IgE-mediated anaphylaxis induced by aspirin. ACI Int 2002; 14: 220-222.
12. Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM, et al. Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989; 62: 295-298.
13. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975; 1: 67-69.
14. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3: 588-593.
15. Stevenson DD, Lewis RA, Proposed mechanism of aspirin sensitivity reactions. J Allergy Clin immunol 1977; 80: 788-790.
16. Szczeklik A, Sanak M. Molecular mechanisms in aspirin-induced asthma. ACI Int 2000; 12: 171-178.
17. Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994; 94: 1046-1056.
18. Nasser SM, Lee TH. Leukotrienes in aspirin-sensitive asthma. In: Szczeklik A, Gryglewski R J, Vane J. eds. Eicosanoids, aspirin and asthma Marcel Dekker, New York 1998; pp 317-336.
19. Lee TH, Smith CM, Arm JP, Christie PE. Mediator release in aspirin-induced reactions. J Allergy Clin Immunol 1991; 88: 827-829.
20. Cowburn AS, Sladek K, Soja J, Adamek L, Nizankowska E, Szczeklik A, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834-846.
21. Sanak M, Simon H-U, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599-2000.
22. Sanak M, Szczeklik A. Genetics of aspirin induced asthma. Thorax 2000; 55 (Suppl 2): S45-S47.
23. Van Sambeck R, Stevenson DD, Baldasaro M, Lam BK, Zhao JL, Yoshida S, et al. 5' Flanking region polymorphism of the gene encoding leukotrienc C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000; 106: 72-76.
24. Torres-Galvan MJ, Ortega N, Sanchez-Garcia F, Blanco C, Carrillo T, Quiralte J. LTC4-synthase A-444C polymorphism: lack of association with NSAID-induced isolated periorbital angioedema in a Spanish population. Ann Allergy Asthma Immunol 2001; 87: 506-510.
25. Kawagishi Y, Mita H, Taniguchi M, Maruyama M, Oosaki R, Higashi N, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma J Allergy Clin Immunol 2002; 109, 936-942.
26. Kedda MA, Shi J, Duffy D, Phelps S, Yang L, O'Harn K, et al. Characterization of two polymorphisms in the leukotriene C-4 synthase gene in an Australian population in subjects with mild, moderate and severe asthma. J Allergy clin Immunol 2004; 113: 889-95.
27. Choi JH, Park HS, Oh HB, Lee JH, Sub YJ, Park CS, et al. Leukotriene-related gene polymorphism in ASA-intolerant asthma: an association with a haplotype of 5 lipoxygenase. Hum Genet 2004; 114: 337-44.
28. Stevenson DD, Simon PA. Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW. eds. Allergy: Principles and practice Mosby, St. Louis 1998; pp. 1225-1234.
29. Czech W, Kapp A, Kownatzki E, Schöpf E. Die Bedeutung der in vitro-induzierten Histaminfreisetzung aus isolierten Leukozyten für die Diagnostik pseudo-allergischer Reaktionen auf Azetylsalizylsäure. Allergologie 1990; 13: 201-204.
30. Lebel B, Messaad B, Kvedariene V, Rongier M, Bousquet J, Demoly P. Cysteinyl-leukotriene release test (CAST) in the diagnosis of immediate drug reactions. Allergy 2001; 56: 688-692.
31. De Weck AL, Stadler BH, Urwyler A, Wechsner HU, Bühlmann RP. Cellular antigen stimulation test (CAST): a new dimension in allergy diagnosis. Allergy Clin Immunol News 1993; 5: 9-14.
32. De Week AL. Zellulärer Allergen De -Stimulierungs-Test (CAST). Eine Uebersicht und kritische Auswertung der klinischen Anwendung in der Allergiediagnose. Allergologie 1997; 20: 487-502.
33. De Week AL, Sanz ML. Cellular Allergen Stimulation Test (CAST) 2003: a review. J Investig Allergol Clin Immunol 2004; 14: 253-73.
34. Kubota Y, Imayama S, Toshitani A, Miyahara H, Tanahasshi T, Uemura Y, et al. Sulfidoleukotriene release test (CAST) in hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 1997; 114: 361-366.
35. Mewes T, Riechelmann H, Klimek L. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps and aspirin intolerance. Allergy 1996; 51: 506-510.
36. May A, Weber A, Gall H, Kaufmann R, Zollner TM. Means of increasing sensitivity of an in vitro diagnostic test for aspirin intolerance. Clin Exp Allergy 1999; 29: 1402-1411.
37. Pierzchalska M, Mastalerz; L, Sanak M, Zalula M, Szczeklik A. A moderate and unspecific release of cysteinyl leukotrienes by aspirin from peripheral blood leukocytes precludes its value for aspirin sensitivity testing in asthma. Clin Exp Allergy 2000; 30; 1785-1791.
38. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nosteroidal anti-inflammatory drugs Int Arch Allergy 2005; 36: 58-72.
39. Sabbah A, Drouet M, Sainte-Laudy J, Lauret MG, Loiry M. Apport de la cytométrie en flux dans le diagnostic allergologique. Allergie Immunol 1997; 29: 15-21.
40. Sanz ML, Sánchez G, Gamboa PM, Vila L, Uasuf C, Chazot M, et al. Ag-induced basophil activation: CD 63 cell expression detected by flow cytometry in allergic patients to Dermatophagoides pteronyssinus and Lolium perenne. Clin Exp Allergy 2001; 31: 1007-1013.
41. Hauswirth AW, Natter S, Ghanaddan M, Majlesi Y, Schernthaner GH, Sperr WR, et al. Recombinant allergens promote expression of CD 203c on basophils of sensitized individuals. J Allergy Clin Immunol 2002; 110: 102-9.
42. Garcia-Aviles C, Sanchez-Lopez G, Sanz ML, Uasuf C, Dieguez I, Chazot M, et al. Flow cytometric Allergen Stimulation Test (FAST) in the in vitro diagnosis of food allergy. Allergy 2000; 55 (Suppl 63): 128.
43. Monneret-Vautrin D, Sainte-Laudy J, Kanny G, Frémont S. Human basophil activation measured by CD63 expression and LTC4 release in IgE-mediated food allergy. Ann Allergy Asthma Immunol 1999; 82: 33-40.
44. Diaz-Perales A, Sanz ML, Garcia-Casado G, Sanchez-Monge R, Garcia-Selles FJ, Lomardero M, et al. Recombinant Pru p 3 and natural Pru p 3. A major peach allergen, show equivalent immunological reactivity: a new tool for the diagnosis of fruit allergy. J Allergy Clin Immunol 2003; 111: 628-33.
45. Erdman SM, Heusen N, Moll-Slodowy S, Merk HF, Sachs B. CD63 expression on basophils as a tool for the diagnosis of pollen-associated food allergy: sensitivity and specificity. Clin Exp Allergy 2003; 33: 607-14.
46. Erdman SM, Sachs B, Schmidt A, Merk HF, Scheiner O, Moll-Shodowy S, et al. In vitro analysis of birch pollen-associated food allergy by use of recombinant allergens in then basophil activation test. Int Arch Allergy Immunol 2005; 136: 230-8.
47. Ebo DG, Hagendorens MM, Bridts CH, Schuerwegh AJ, De Clerck L S, Stevens W J. Flow cytometric analysis of in vitro activated basophils, specific IgE and skin tests in the diagnosis of pollen-associated food allergy. Cytometry B Clin Cytom 2005; 64: 28-33.
48. Sainte-Laudy J, Sabbah A, Drouet M, Lauret MG, Loiry M. Diagnosis of venom allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, histamine and leukotriene C4 release. Clin Exp. Allergy 2000; 30: 1166-1171.
49. Binder M, Fierlbeck G, King T, Valent P, Buhring HJ. Individual hymenoptera venom compounds induce upregulataion of the basophil activation marker cytonucleotide pyrophosphatase/phosphodiesterase 3 (CD203c) in sensitized patients. Int Arch Allergy Immunol 2002; 129: 160-8.
50. Eberlein-König B, Rakoski J, Behrendt H, Ring J. Use of CD63 expression as marker of in vitro basophil activation in identifying the culprit in insect venom allergy. J Invest Allergol Clin Immunol 2004; 14: 10-6.
51. Erdman SM, Sachs B, Kwiecien R, Moll-Slodowy S, Sauer L-. Merk HF. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. Allergy 2004; 59: 1102-9.
52. Sturm GJ, Bohm F, Trummer M, Weiglhofer I, Heinemann A, Aberer W. The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study. Allergy 2004; 59: 1110-7.
53. Ebo DG, Lechkar B, Schuerwegh AJ, Bridts CH, De Clerk LS, Stevens WJ. Validation of a two-color flow cytometric assay detecting in vitro basophil activation for the diagnosis of IgE-mediated natural rubber latex allergy. Allergy 2002; 57: 706-712.
54. Sanz ML, Gamboa PM, Garcia-Aviles C, Vila L, Dieguez I, Antepara I, et al. Flow-cytometric cellular alllergen stimulation test in latex allergy. Int Arch Allergy Immunol. 2003; 130: 33-39.
55. Hemery ML, Arnoux B, Dhivert-Donnadieu H, Rongier M, Barbotte E, Verdier R, et al. Confirmation of the diagnosis of natural rubber latex allergy by the Basotest method. Int Arch Allergy Immunol 2005; 136: 53-7.
56. Sanz ML, Gamboa PM, Uasuf C, Vila L, Garcia-Aviles C, Chazot M, et al. Flow-cytometric basophil activation test by detection of CD63 expression in patients with immediate type reactions to Beta-lactam antibiotics. Clin. Exp. Allergy 2002; 32: 277-286.
57. Sanz ML, Gamboa PM, de Weck AL. Clinical evaluation of in vitro diagnostic tests in diagnosis of immediate allergic reactions to β-lactam antibiotics. ACI Int 2002; 14: 185-193.
58. Torres MJ, Padial A, Mayorga C, Fernandez T, Sanchez-Sabate E, Cornejo-Garcia JA, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams, Clin Exp Allergy 2004; 34: 1768-75.
59. Gamboa PM, Garcia-Aviles MC, Urrutia I, Antepara I, Esparza R, Sanz ML. Basophil activation and sulfidoleukotriene production in patients with immediate allergy to betalactam antibiotics and negative skin tests, J Invest Allergol Clin Immunol 2004; 14: 278-83.
60. Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I, et al. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003; 58: 312-317.
61. Abuaf N, Rajoely B, Ghazouani E, Levy DA. Pecquet C, Chabane H, et al. Validation of flow cytometry assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy. J Allergy Clin Immunol 1999; 104: 411-418.
62. Monneret G, Benoit Y, Debard AL, Gutowski MC, Topenot I, Bienvenu J. Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs: Clin Immunol 2002; 102: 192-199.
63. Sudheer PS, Hall JF, Read GF, Rowbottom AW, Wiliams PE. Flowcytometric investigation of peri-anaesthetic anaphylaxis using CD63 and CD203c. Anaesthesia 2005; 60: 251-6.
64. Gamboa PM, Sanz ML, Caballero MR, Urrutia I, Antepara I, Esparza I, et al. The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin exp Allergy 2004; 34: 1448-57.
65. Sanz ML, Maselli JP, Gamboa PM, Garcia-Aviles MC, Oehling A, Diéguez I, et al. Flow-cytometric basophil activation test. A review. J. Invest Allergol Clin Immunol 2002: 12: 143-154.
66. De Weck AL, Sanz ML. Flow cytometric Cellular Allergen Stimulation Test (FAST / Flow CAST): technical and clinical evaluation of a new diagnostic test in allergy and pseudo-allergy. ACI Int 2002; 14: 204-215.
67. Ebo DG, Hagendorens MM, Bridts CH, Scheurwegh AJ, De Clerck LS, Stevens WJ. In vitro allergy diagnosis: should we follow the flow? Clin Exp Allergy 2004; 34: 332-9.
68. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004; 113: 771-5.
69. Rachelefsky GS, Coulson A, Siegel SC, Stiehm ER. Aspirin intolerance in chronic childhood asthma: detected by oral challenge. Pediatrics 1975; 56: 443-448.
70. Yunginger JW, O'Connell EJ, Logan GB. Aspirin-induced asthma in children. J Pediatrics 1973; 82: 218-221.
71. Settipane GA. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review. Allergy 1980; 35: 149-15.
72. Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS. Aspirin-sensitive rhinosinusitis/asthma: spectrum of adverse reactions to aspirin. J Allergy Clin Immunol 1983; 71: 574-579.
73. Quiralte J, Blanco C, Castillo P, Delgado J, Carillo T. Immunodeficiency and other clinical findings. Intolerance to nonsteroidal anti-inflammatory drugs. Results of a control challenge in 98 patients. J Allergy Clin Immunol 1996; 98: 3-10.
74. SzczekliK A, Nizankowska E, Duplaga M, on behalf of the AIANE investigators. Natural history of aspirin-induced asthma. Eur Respir J 2000; 16: 432-436.
75. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002; 89: 474-478.
76. Sladek K, Szczeklik A. Cyteinyl leukotrienes overproduction and mast cell activation in aspirin provoked bronchospasm in asthma. Eur Respir J 1993; 6: 391-399.
77. O'Sullivan S, Dahlen B, Dahlen S-E, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9α, 11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996; 98: 421-432.
78. Mita H, Endoh S, Kudoh M, Kawagishi Y, Kobayashi M, Taniguchi M, et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001; 56: 1061-1067.
79. Bochenek G, Nagraba K, Nizandowska E, Szczeklik A. A controlled study of 9α, 11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls following the aspirin challenge. J Allergy Clin Immunol 2003; 111: 743-7.
80. Basomba A, Romar A, Pelaez A, Villamanzo LG, Campos A. The effect of sodium cromoglycate in preventing aspirin-induced bronchospasm. Clin Allergy 1976; 6: 269-275.
81. Robuschi M, Gambaro G, Sestini P. Pieroni MG, Refini RM, Vaghi A, et al. Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium Am J Respir Crit Care Med 1997; 155: 1461-1464.
82. Kowalski ML, Ptasinska A, Bienkiewicz B, Pawliczak R, DuBuske L. Differential effects of aspirin and misoprostol on 15-hydroxyeicosa-tetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J Allergy Clin Immunol 2003; 112: 505-512.
83. Kowalski ML, Grzegirczy KJ, Wojciechowska B, Poniatowska M. Intranasal challenge with aspirin induces cell influx and activation of eosinophils and mast cells in nasal secretions of ASA sensitive patients. Clin Exp Allergy 1996; 26: 807-814.
84. Lenz P, Czech W, Schöpf E, Kapp A. Eosinophils, critical target cells in pseudo-allergic reactions to acetylsalicylic acid? Arch Derm Res 1994; 286: 223-230.
85. Nasser SM, Pfister R, Christie P, Sousa AR, Barker J, Schmitz-Schumann M, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Resp Crit Care Med 1996; 153: 90.
86. Mita H, Higashi N, Taniguchi M, Higashi A, Kawagishi Y, Akiyama K. Urinary 3-bromotyrosine and 3-chlorotyrosine concentration in asthmatic patients: lack of increase in 3-bromotyrosine concentration in urine and plasma proteins in aspirin-induced asthma after intravenous aspirin challenge. Clin exp Allergy 2004; 34, 931-938.
87. Pearson DJ, Suarez-Mendez VJ. Abnormal platelet hydrogen peroxide metabolism in aspirin hypersensitivity. Clin Exp Allergy 1990; 20: 157-163.
88. Tornhamre S, Ehnhage A, Köllbeck KG, Edenius C, Lindgren A. Uncoupled regulation of leukotriene C4 synthase in platelets from aspirin-intolerant asthmatics and healthy volunteers after aspirin treatment. Clin Exp Allergy 2002; 32: 1566-1573.
89. Ameisen JC, Capron A, Joseph M, Maclouf J, Vorng H, Pancre V, et al. Aspirin-sensitive asthma: abnormal platelet response to drugs inducing asthma attacks. Int Arch Allergy Appl. Immunol 1985; 78: 438-448.
90. Wojnar RJ, Hearn T, Starkweather S. Augmentation of allergic histamine release from human leukocytes by nonsteroidal anti-inflammatory-analgesic agents. J Allergy Clin Immunol 1980; 66: 37-45.
91. Spielberg HL. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive patients during reactions to aspirin. Ann Rev Respir Dis 1988; 137: 305-311.
92. Bosso JV, Schwartz LB, Stevenson DD. Tryptase and histamine release during aspirin-induced respiratory reactions. J Allergy Clin Immunol 1991; 88: 830-837.
93. Oosting E, Kardaun SH, Doeglas HM, Los P, de Monchy JG. Increased urinary excretion of the histamine metabolite N tau-methylhistamine during acetylsalicylic acid provocation in chronic urticaria patients. Agents Actions 1990; 30: 254-257.
94. Misso NI, Aggarwal S, Phelps S, Beard R, Thompson PJ. Urinary leukotriene E4 and 9 alpha, 11 beta-prostaglandin F (2) concentrations in mild, moderate and severe asthma, and in healthy subjects. Clin Exp Allergy 2004; 34: 624-31.
95. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostasglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis 1988; 137: 847-854.
96. Kumlin M, Dahlen B, Björck T, Zetterstrom O, Granstrom E, Dahlen S-E. Urinary excretion of leukotriene E4 and 11-dehydro thromboxane B2 in reponse to bronchial provocations with allergen, aspirin, leukotriene D4 and histamine in asthma. Am Rev Respir Dis 1992; 146: 96-103.
97. Higashi N, Taniguchi M, Mita H, Kawagishi Y, Ishii T, Higashi A, et al. Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrieneuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2004; 113: 277-283.
98. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma..Am J Respir Crit Care Med 2002, 166: 301-306.
99. Picado C, Ramis I, Rosello J, Prat J, Bulbena O, Plaza V, et al Release of peptide leukotriene into nasal sceretions after local instillations of aspirin in aspiri-sensitive asthmatic patients. Am Rev Respir Dis 1992; 145: 65-69.
100. Dahlen SE, Malmström K, Nizankowska E, Dahlen B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist. Am J Respir Crit Care Med 2002; 165: 9-14.
101. Mastalerz L, Gawlewixz-Mroczka A, Nizandowska E, Cmiel A, Szczeklik A. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2000; 32: 1360-1365.
102. Yoshida S, Sakamoto H, Ishizaki Y, Onuma. K, Shoji T, Nakagawa H, et al. Efficacy of leukotriene receptor antagonist in bronchial hyperresponsiveness and hypersensitivity to analgesic in aspirin-intolerant asthma. Clin Exp Allergy 2000; 30: 64-70.
103. Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H. Elevated complement C3a in plasma from patients with severe acute asthma J Allergy Clin Immunol 2003; 112: 525-30.
104. Ali H, Panettieri RA. Anaphylatoxin C3a receptors in asthma Respire Res 2005; 21: 19.
105. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, et al. A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406: 998-1001.
106. Hansch GM, Voigtlander V, Rother U. Effect of aspirin on the complement system in vitro. Int Arch Allergy Appl Immumol 1980; 61: 150-158.
107. Hansch GM, Romer W, Voigtlander V, Rother U. Effect of salicylates on the complement system: generation of mediators in vivo and in vitro. Clin Immunol Immunopathol 1981; 21: 228-236.
108. Voigtlander V, Hansch GM, Rother U. Effect of aspirin on complement in vivo. Int Arch Allergy Appl Immunol 1980; 61: 145-149.
109. Pleskow WW, Chenoweth DE, Simon RA, Stevenson DD, Curd JG. The absence of detectable complement activation in aspirin-sensitive asthmatic patients during aspirin challenge. J Allergy Clin Immunol 1983; 72: 462-468.
110. Mita H, Higashi N, Taniguchi M, Higashi A, Akiyama K. Increase in urinary leukotriene B4 glucuronide concentration in patients with aspirin-intolerant asthma alter intravenous aspirin challenge. Clin Exp Allergy 2004; 34: 1262-9.
111. Hollingworth HM, Downing ET, Braman SS. Glassroth J, Binder R, Center DM. Identification and characterisation of neutrophil chemotactic activity in aspirin-induced asthma. Am Rev Respir Dis 1984; 130: 373-379.
112. Ortolani C, Capsoni F, Restuccia M, Pastorello E, Riboldi PS, Zocchi M, et al. Neutrophil chemotactic factor of anaphylaxis (NCF-A) release in aspirin-induced asthma. Clin Allergy 1984; 14: 443-452.
113. James JM, Kagey-Sobotka A, Sampson HA. Patients with severe atopic dermatitis have activated circulating basophils. J Allergy Clin Immunol 1993; 81: 1155-1162,
114. Okada H, Onishi T, Hirashima M, Fujita J, Yamaji Y, Takahara J, et al. Anti-asthma effect of an antiviral drug, acyclovir: a clinical case and experimental study. Clin Exp Allergy 1997; 27: 431.
115. Nakagawa H, Yoshida S, Nakabayashi M, Akahori K, Shoji T, Hasegawa H, et al. Possible relevance of virus infection for development of analgesic idiosyncrasy. Respiration 2001; 68: 422-424.
116. Okada H, Onishi T, Hirashima M, Fujita J, Yamaji Y, Takahara J, et al. Anti-asthma effect of an antiviral drug, acyclovir: a clinical case and experimental study. Clin Exp Allergy 1997; 27: 431-437.
117. Yoshida S, Sakamoto H, Yamawaki Y, Shoji T, Akahori K, Onuma K, et al. Effect of acyclovir on bronchroconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma. J Allergy Clin Immunol 1998; 102: 909-914.
118. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988; 18: 15-20.
119. Mastalerz L, Milewski M, Duplaga M, Nizandiwska E, Szczeklik A. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy 1997; 52: 895-900.
120. Nizankowska E, Szczeklik A. Glucocorticosteroids attenuate aspirin-precipitated adverse reactions in aspirin-intolerant patients with asthma. Ann Allergy 1989; 63: 159-162.
121. Kawano T, Matsuse H, Kondo Y, Machida I, Saeki S, Tomari S, et al. Tacrolimus reduces urinary excretion of leukotriene E(4) and inhibits aspirin-induced asthma to threshold dose of aspirin. J Allergy Clin Immunol 2004; 114: 1278-81.
122. Biedermann T, Hartmann K, Sing A, Przybilla B. Hypersensitivity to non-steroidal anti-inflammatory drugs and chronic urticaria cured by treatment of Blastocystis hominis infection. Br J Dermatol 2002; 146:1113-1114.
123. Smith AP. Response of aspirin-allergic patients to challenge by sdme analgesics in common use. Br. Med. J 1971; 2: 494-496.
124. Settipane GA, Stevenson DD. Cross-sensitivity with acetaminophen in aspirin sensitive subjects with asthma. J Allergy Clin Immunol 1989; 84:26-33.
125. Perrone MR, Artesani MC, Viola M, Gata F, Cringi M, Quaratino D, et al. Tolerability of rofecoxibe in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: A study of 216 patients and literature review. Int Arch Allergy Immunol 2003; 132: 82-6.
126. Szczeklik A, Sanak M. The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selctive inhibitors. Clin Exp Allergy 2002; 32: 339-342.
127. Matucci A, Parronchi P, Vultaggio A- Rossi O, Brugnolo C, Maggi E, et al. Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. Allergy 2004; 59: 1113-4.
128. Doeglas HM. Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br J Dermatol 1975; 93: 135-144.
129. Serhan CN, Sheppard KA, Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. Proc Natl Acad Sci USA 199; 94: 9967-9972.
130. Sanak M, Levy BD, Clish CB, Chiang; N, Gronert K, Mastalerz L, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16: 44-49.
131. Sousa AR, Parkih A, Scadding G, Corrigan CJ, Lee TH. Leukotriene receptor expression on nasal mucosal inflammatory cells in apsirin-sensitive rhinosinusitis. N Engl J Med 2002; 347: 1493-1499.
132. Szczeklik A, Czerniawska G, Nizandowska, E. Allergische und pseudoallergische Reaktionen auf Pyrazolonpräparate. In: Brune K, Lanz R, eds. 100 Jahre Pyrazolone Urban & Schwarzenberg, München 1985; pp. 247-252.
133. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003 111: 882-888.
134. Okasaki T, Ilea VS, Rosario NA, Reisman RE, Arbesman CE, Lee JR, et al. Regulatory role of prostaglandin E in allergic histamine release with observations on the responsiveness of basophil leukocytes and the effect of acetylsalicylic acid. J Allergy Clin Immunol 1977; 60: 360-366.
135. Schäfer D, Lindenthal U, Wagner M, Bolkcskei EL, Baekler HW. Effect of prostaglandin E2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa. Thorax 1996; 51: 919-923.
136. Celik G, Bavbeck S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E2 on this release from peripheral blood leukocytes in aspirin-induced asthmatic patients. Clin Exp Allergy 2001; 31: 1615-1622.
137. Schäfer D, Schmid M, Gode UC, Baenkler BW. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics, Eur Respir J 1999; 13: 638-646.
138. Szczeklik A. Prostaglandin E2 and aspirin-induced asthma. Lancet 1995;345:1056.
139. Raud J, Sydbom A, Dahlen SE, Hedqvist P. Prostaglandin E2 prevents diclofenac-induced enhancement5 of histamine release and inflammation evoked by in vivo challenge with compounds 48/80 in the hamster cheek pouch. Agents Actions 1989; 28: 108-14.
140. Sergeeva MG, Gonchar MV, Mevkh AT, Varfolomeyev SD. Prostaglandin E2 biphasic control of lymphocyte proliferation: inhibition by picomolar concentrations. FEBS Lett 1997; 418: 235-8.
141. Pavord ID, Tattersfield AF. Bronchoprotective role for endogenous prostaglandin E. Lancet 1995; 345: 436-438.
142. Szczeklik A, Mastalerz; L, Nizandowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996; 153: 567-571.
143. Sestini P, Armetti L, Gambaro G, Pieroni MG, Refini RM, Sala A, et al. Inhaled PgE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma Am J Respir Crit Care Med 1996; 153: 572-575.
144. Hecksteden K, Schäfer D, Stuck BA, Klimek L, Hörmann K. Diagnostik der Analgetika-Intoleranz-Syndroms mittels funktioneller Zelltestung (Analgetika-Intoleranz-Test: AIT) Allergologie 2003: 26: 263-271.
145. Pierzchalska M, Szabo Z, Sanak M, Soja J, Szczeklik A. Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients with special reference to aspirin-induced asthma. J Allergy Clin Immunol 2003; 111: 1041-1048.
146. Abrahamsen O, Haas H, Schreiber J, Schlaak M. Differential mediator release from basophils of allergic and non-allergic asthmatic patients after stimulation with anti-IgE and C5a. Clin Exp Allergy 2001; 31: 368-378.
147. Czech W, Schöpf E, Kapp A. Release of sulfidoleukotrienes in vitro: Its relevance in the diagnosis of pseudoallergy to acetylsalicylic acid. Inflamm Res 1995; 44: 291-295.
148. Wedi B, Kapp A. Aspirin induced adverse skin reactions: new pathophysiological aspects. Thorax 2000; 55 (Suppl 2): S70-S71.
149. Okuda Y, Hattori H, Takashima T, Miyatake A, Yamatodani A, Tsuyuguchi I, et al. Basophil histamine release by platelet activating factor in aspirin-sensitive subjects with asthma. J Allergy Clin Immunol 1990; 86: 548-553.
150. Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109: 114-8.
151. Bischoff SC, De Weck AL, Dahinden CA. Interleukin 3 and granulocyte/ macrophage -colony-stimulating factor render human basophils responsive to low concentrations of complement component C5a. Proc Natl Acad Sci USA 1990; 87: 6813-7.
152. Sanak M, Sampson AP. Biosynthesis of cysteinyl-leukotrienes in aspirin-intolerant asthma. Clin Exp Allergy 1999; 29, 306-313.
153. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma, J Allergy Clin Immunol 2004; 114: 248-253.
154. Williams WR, Pawlowicz A, Davies BH. In vitro tests for the diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol 1990; 86: 445-451.
155. Schlumberger HD, Lutteke EK, Kallos P. Acetylsalicylic acid intolerance, Acta Med Scand 1974; 196: 451-458.
156. Weltman JK, Szaro RP, Settipane GA. An analysis of the role of IgE in intolerance to aspirin and tartrazine. Allergy 1978; 33: 273-281.
157. Phills JA, Perelmutter L. IgE-mediated and non IgE- mediated allergic-type reactions to aspirin. Acta allergol 1974; 29: 474-477.
158. Zhu D, Becker WM, Schulz KH, Schubeler K, Schlaak M. The presence of specific IgE to slicyloyl and O-methyl salicyloyl in aspirin sensitive patients. Asia Pac J Allergol Clin Immunol 1992; 10: 25-32.
159. Zhu D, Becker WM, Schulz KH, Schubeler K, Schlaak M. Detection of IgE antibodies specific for 1-phenyl-2,3-dimethyl-3-pyrazoline-5-one by RAST: a serological diagnostic method for sensitivity to pyrazoline drugs. Asian Pac J Allergy Immunol 1992; 10: 95-101.
160. Zhu Daxun, Becker WM, Schulz KH, Schlaak M. Sensitivity to aspirin: A new serological diagnostic method. J Invest Allergol Clin Immunol 1993; 3: 72-78.
161. Zhu DX, Zhao JL, Li HL. Drug allergy identification and characterization of IgE reactivity to aspirin and related compounds Asia Pac J Allergy Clin Immunol 1997; 7: 260-268.
162. Girard JP, Hildebrandt F, Favre H. Hypersensitivity to aspirin: Clinical and immunological studies. Helvetica Med Acta 1969; 35: 86-95.
163. Sanz ML, Prieto I, Oehling A. The histamine release test as an important complement to the diagnosis of allergic diseases. ACI News 1995; 7: 56-60.
164. Demoly P, Lebel B, Arnoux B. Allergen-induced mediator release tests. Allergy 2003; 58: 553-559.
165. Kurimoto Y, De Week AL, Dahinden CA. The effect of interleukin 3 upon IgE-dependent and IgE-independent basophil degranulation and leukotriene generation. Eur J Immunol 1991: 21: 361-8.
166. Busse A, Czech W, Schöpf E, Simon JC. Der CAST-ELISA in der Diagnostik von pseudoallergischan Reaktionen gegen Nahrung-smitteladditiva und Azetylsalizylsäure. Allergologie 2000; 23: 110-115.
167. Wolanczyk-Medrala A, Medrala A, Malolepszy J, Liebhart J, Marszalska M, Dobek R, et al. CAST-ELISA test in diagnosis of aspirin-induced asthma 1997; submitted.
168. Wolanczyk-Medrala A, Matolepszy J, Medrala W, Leibhart J, Linva M, Pietrzak M. CAST-ELISA test in diagnosis of aspirin idiosyncrasy in aspirin-induced asthma. Allergy 1995; 50(Suppl 26): 246.
169. Brunner B, Eberein-König, Pryzbilla B. Histamine and sulfidoleukotriene release from peripheral blood leukocytes (PBL) of patients with anaphylactoid reactions provoked by acetylsaliciylic acid (ASA). J Allergy clin Immunol 1996; 97: 344.
170. Sainte Laudy J. Intérêt de l'étude in vivo et in vitro des leucotrienes. Application au cas particulier de l'aspirine. Allerg Immunol (Paris) 1998; 30: 28-34.
171. Erbagci Z. Multiple NSAID intolerance in chronic idiopathic urticaria is correlated with delayed, pronounced and prolonged autoreactivity. J Dermatol 2004; 31: 376-82.
172. Giymesi E, Sipka S, Danko K, Kiss E, Hidvegi B, Gal M, et al. Basophil CD63 expression assay on highly sensitized atopic donor leukocytes- a useful method in chronic autoimmune urticaria. Br J Dermatol 2004: 151: 388-96.
173. Szczeklik A, Nizankowska E, Serafin A, Dyxzek A, Duplaga M, Musial J. Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995; 152: 1753-1756.
174. Simon RA. Treatment of patients with respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep 2004; 4: 139-143.
175. Stevenson DD, Hankammer MA, Mathison DD. Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98: 751-75.
176. Kowalski ML. Management of aspirin-sensitive rhinosinusitis asthma syndrome: what role for aspirin desensitization? Allergy Proc 1992; 13: 75-84.
177. Berges-Gimeno M, Simon RA, Stevenson DD. Treatment with aspirin desensitization in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111: 180-186.
178. Asanuma M, Miyazaki I, Ogawa N. Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases. Curr Pharm Des 2004; 10(6): 695-700.
179. Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 2005; 11(14): 1795-804.
180. Salvi GE, Lang NP. The effects of non-steroidal anti-inflammatory drugs (selective and non-selective) on the treatment of periodontal diseases. Curr Pharm Des 2005; 11(14): 1757-69.